Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2003 1
2004 1
2005 1
2006 1
2010 1
2012 1
2014 1
2015 3
2016 3
2017 6
2018 4
2019 2
2020 1
2021 3
2022 3
2023 6
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Agarwal R, et al. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5. N Engl J Med. 2025. PMID: 40470996 Clinical Trial.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Sarafidis P, et al. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7. Clin J Am Soc Nephrol. 2023. PMID: 36927680 Free PMC article. Clinical Trial.
Advances in Alzheimer's disease's pharmacological treatment.
Conti Filho CE, Loss LB, Marcolongo-Pereira C, Rossoni Junior JV, Barcelos RM, Chiarelli-Neto O, da Silva BS, Passamani Ambrosio R, Castro FCAQ, Teixeira SF, Mezzomo NJ. Conti Filho CE, et al. Among authors: castro fcaq. Front Pharmacol. 2023 Jan 26;14:1101452. doi: 10.3389/fphar.2023.1101452. eCollection 2023. Front Pharmacol. 2023. PMID: 36817126 Free PMC article. Review.
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE investigators. Agarwal R, et al. Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022. Nephrol Dial Transplant. 2025. PMID: 39916475 Free PMC article. Clinical Trial.
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Gheorghiade M, et al. JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734. JAMA. 2015. PMID: 26547357 Clinical Trial.
Case Report: Human Bertiellosis in Brazil.
Passamani-Ambrósio R, Pereira GP, Miranda IR, Barcelos RM, Rossoni JV, Loyola YCS, Castro FCAQ, Colombo FA, Marques MJ, Rodrigues EA, Graeff-Teixeira C, Marcolongo-Pereira C. Passamani-Ambrósio R, et al. Among authors: castro fcaq. Am J Trop Med Hyg. 2022 Nov 14;108(1):34-36. doi: 10.4269/ajtmh.22-0435. Print 2023 Jan 11. Am J Trop Med Hyg. 2022. PMID: 36375464 Free PMC article.
Neurobiological mechanisms of mood disorders: Stress vulnerability and resilience.
Marcolongo-Pereira C, Castro FCAQ, Barcelos RM, Chiepe KCMB, Rossoni Junior JV, Ambrosio RP, Chiarelli-Neto O, Pesarico AP. Marcolongo-Pereira C, et al. Among authors: castro fcaq. Front Behav Neurosci. 2022 Oct 28;16:1006836. doi: 10.3389/fnbeh.2022.1006836. eCollection 2022. Front Behav Neurosci. 2022. PMID: 36386785 Free PMC article. Review.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M; CREDENCE Trial Investigators. Yi TW, et al. Am J Kidney Dis. 2023 Jul;82(1):84-96.e1. doi: 10.1053/j.ajkd.2022.12.015. Epub 2023 Mar 7. Am J Kidney Dis. 2023. PMID: 36889425 Clinical Trial.
41 results